Soligenix Stock Nearly Doubles Before the Bell as Ebola Vaccine Hopes Put Tiny Biotech Back in Play

Soligenix Inc. shares nearly doubled in pre-market trading on Wednesday after the low-priced biotech tied its ThermoVax vaccine-stabilization technology to the Bundibugyo Ebola outbreak in Congo and Uganda, extending a sharp gain from Tuesday’s regular session. Google Finance showed SNGX at $1.00 pre-market, up 94.6% from a $0.51 close; a market-data feed listed the latest regular-market price at $0.513.

27 May 2026

NASDAQ:SNGX · Stock Market

#1

Consumer Confidence • 10:00 ET

A large surprise can reset expectations for household spending and near-term growth, with read-through to Treasuries, USD and cyclical stocks.

#2

New Home Sales • 10:00 ET

Housing remains highly rate-sensitive; the print can move homebuilders, mortgage-sensitive names and the long end of the Treasury curve.

#3

Intuit earnings • After close

Guidance can influence software multiples and sentiment around U.S. small-business activity.

View full calendar